Docosanoic acidCAS# 112-85-6 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 112-85-6 | SDF | Download SDF |
| PubChem ID | 8215 | Appearance | Powder |
| Formula | C22H44O2 | M.Wt | 340.6 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Synonyms | Behenic acid | ||
| Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
| Chemical Name | docosanoic acid | ||
| SMILES | CCCCCCCCCCCCCCCCCCCCCC(=O)O | ||
| Standard InChIKey | UKMSUNONTOPOIO-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C22H44O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22(23)24/h2-21H2,1H3,(H,23,24) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Docosanoic acid Dilution Calculator
Docosanoic acid Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.936 mL | 14.68 mL | 29.36 mL | 58.7199 mL | 73.3999 mL |
| 5 mM | 0.5872 mL | 2.936 mL | 5.872 mL | 11.744 mL | 14.68 mL |
| 10 mM | 0.2936 mL | 1.468 mL | 2.936 mL | 5.872 mL | 7.34 mL |
| 50 mM | 0.0587 mL | 0.2936 mL | 0.5872 mL | 1.1744 mL | 1.468 mL |
| 100 mM | 0.0294 mL | 0.1468 mL | 0.2936 mL | 0.5872 mL | 0.734 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Oleic acid
Catalog No.:BCN7159
CAS No.:112-80-1
- Methyl linoleate
Catalog No.:BCN8137
CAS No.:112-63-0
- Methyl Oleate
Catalog No.:BCN8306
CAS No.:112-62-9
- Methyl Stearate
Catalog No.:BCN8309
CAS No.:112-61-8
- Methyl hexadecanoate
Catalog No.:BCN8290
CAS No.:112-39-0
- Acetic acid octyl ester
Catalog No.:BCN8303
CAS No.:112-14-1
- 2-Undecanone
Catalog No.:BCN8461
CAS No.:112-12-9
- Quetiapine fumarate
Catalog No.:BCN5339
CAS No.:111974-72-2
- Quetiapine
Catalog No.:BCC1877
CAS No.:111974-69-7
- Adenanthin
Catalog No.:BCN6000
CAS No.:111917-59-0
- Temocapril
Catalog No.:BCC5013
CAS No.:111902-57-9
- (1S,3R)-ACPD
Catalog No.:BCC6590
CAS No.:111900-32-4
- OctMAB
Catalog No.:BCC7893
CAS No.:1120-02-1
- p-Vinylphenyl O-[beta-D-apiofuranosyl-(1-6)]-beta-D-glucopyranoside
Catalog No.:BCN1619
CAS No.:112047-91-3
- Endoxifen
Catalog No.:BCC7761
CAS No.:112093-28-4
- 3-Hydroxy-2-methylpyridine
Catalog No.:BCN8162
CAS No.:1121-25-1
- (S)-(+)-Modafinic acid
Catalog No.:BCC5158
CAS No.:112111-44-1
- (R)-(-)-Modafinic acid
Catalog No.:BCC5157
CAS No.:112111-45-2
- Ikshusterol 3-O-glucoside
Catalog No.:BCN6001
CAS No.:112137-81-2
- DMAP
Catalog No.:BCC2842
CAS No.:1122-58-3
- Pam3CSK4
Catalog No.:BCC6245
CAS No.:112208-00-1
- 14,15-Didehydrovincamenine
Catalog No.:BCN6002
CAS No.:112219-48-4
- 16-O-Methyl-14,15-didehydroisovincanol
Catalog No.:BCN1618
CAS No.:112237-71-5
- Stigmastane-3,6-diol
Catalog No.:BCN6003
CAS No.:112244-29-8
Sex-Dimorphic Association of Plasma Fatty Acids with Cardiovascular Fitness in Young and Middle-Aged General Adults: Subsamples from NHANES 2003(-)2004.[Pubmed:30347828]
Nutrients. 2018 Oct 20;10(10). pii: nu10101558.
To explore the potential association of plasma fatty acids (FAs) and cardiovascular fitness level (CVFL), data of 449 subjects from 2003(-)2004 National Health and Nutrition Examination Survey (NHANES) were analyzed. Among these 249 men and 200 women, aged 20(-)50 years (33.4 +/- 8.4 year, mean +/- Standard Deviation), 79 low, 166 moderate and 204 high CVFL were categorized by age- and gender- specific percentile, respectively. Twenty-four fatty acids were quantified from fasting plasma. Higher levels of 2 very long-chain saturated FAs (VLSFAs): Arachidic acid (AR1, C20:0) and Docosanoic acid (DA1, C22:0) as well as 2 n-6 polyunsaturated FAs (PUFAs): Arachidonic acid (AA, C20:4n-6) and Docosatetraenoic acid (DTA, C22:4n-6) were observed in the subjects with low CVFL. Notably this association exists only in men. Estimated maximal oxygen consumption (VO2max), the marker for cardiorespiratory fitness, was used for further regression analysis. After the adjustment of potential confounding factors (age, smoking, hypertension status, body mass index (BMI), insulin resistance status, and C-reactive protein (CRP), AA was the only FA correlated with low VO2max in women; while in men AR1, DA1, AA, and DTA remain negatively associated with VO2max. This preliminary analysis suggests a sex-dimorphic relationship between these plasma VLSFAs and n-6 PUFAs with CVFL and merits further investigation.
